Royalty Pharma plc (RPRX)
Royalty Pharma plc Operating Income
| Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | $794.3M | $722.9M | $939.7M | $1,364.4M | $2,623.2M | $1,595.0M | $1,430.7M | $977.5M | $1,492.2M |
Royalty Pharma plc (RPRX) Operating Income comparison analysis
RPRX key stats
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
investors
worldwide
FAQ
1) What is Royalty Pharma plc's Operating Income?
As of today, Royalty Pharma plc's last 12-month Operating Income is $1,543.9M, based on the financial report for Sep 30, 2024 (Q3 2024).
2) What is Royalty Pharma plc's Operating Income growth rate?
Over the last year, Royalty Pharma plc's Operating Income growth was 58.4%. The average annual Operating Income growth rates for Royalty Pharma plc have been 1.8% over the past three years, 3.6% over the past five years.
3) Is Royalty Pharma plc's Operating Income growth rate Good?
Over the last year, Royalty Pharma plc's Operating Income growth was 58.4%, which is higher than industry growth of (0.1%). It indicates that Royalty Pharma plc's Operating Income growth is Good.